Pfizer Acquires Biologics Company To Expand Its Oncology Pipeline

Goodwin
Contact

Goodwin

Last week, Pfizer announced that it will acquire Trillium Therapeutics, a clinical stage immune-oncology company based in Cambridge, Massachusetts. Under the agreement, Pfizer reported that it “will acquire all outstanding shares of Trillium not already owned by Pfizer for an implied equity value of $2.26 billion, or $18.50 per share, in cash,” and its two lead molecules.  These molecules, TTI-622 and TTI-621, are SIRPα-Fc fusion proteins being developed across several indications, with a focus on hematological malignancies. Hematological malignancies are cancers that affect the blood, bone marrow, and lymph nodes, including various types of leukemia, multiple myeloma, and lymphoma.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Contact
more
less

PUBLISH YOUR CONTENT ON JD SUPRA NOW

  • Increased visibility
  • Actionable analytics
  • Ongoing guidance

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide